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PCI registry, despite higher total healthcare costs, the use of DESwas cost-effective
in patients who underwent 2- and 3-vessel PCI than in single vessel PCI.
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OBJECTIVES: In vitro diagnostic (IVD) has a considerable health economic impact:
60% of patients’ information derives from IVD tests, but IVD makes 1% of the total
health care budget in EU (EDMA, 2010). No cost-effectiveness (CE) analyses are
available onmolecular IVD in allergy; only NICE in the UKmade a CE study IgE IVD
for peanut allergy (PA). Given the impact of PA on quality of life (Qaly), accurate
diagnosis is crucial. 10%of children are considered peanut sensitised, but only 1-2%
is true positive for PA. Subjects with IgE antibodies to allergens Ara h1-2-3 have
high risk of allergic reactions (Astier, 2006). DBPCFC is the gold standard for food-
allergy diagnosis; however it is time-consuming, expensive and might induce se-
vere reactions (Nicolau, 2010). IVD can give clinicians a tool to decide the need of
DBPCFC (Sastre, 2010); is IVD CE compared to DBPCFC in suspected PA children in
EU, US and Japan?METHODS: Data was collected at Stockholm’s Sach=s Children’s
hospital (Nilsson, 2011) and from published literature. A 5-year Markov simulation
model comparing IVD (ImmunoCap® - allergens f13, Ara h 1- 2-3-8-9) with DBPCFC
was developed with Tree AgePro®, to analyse CE for IVD and the incremental cost
per Qaly in suspected PA children. The sensitivity and specificity of each diagnos-
tics determines the percentage of patients true-allergic, false-allergic, true-healthy
and false-healthy. BaseCase® was used to interactively visualize results. Results
are presented from the health care perspective; care giver indirect costs are in-
cluded in a sensitivity analysis. RESULTS: IgE IVD is CE and cost saving for children
with suspected PA in multiple countries compared to golden standard DBPCFC.
CONCLUSIONS: IVD is a CE alternative to DBPCFC in selected patients in multiple
countries. DBPCFCmight be replaced in selected cases, still being useful in subjects
with conflicting immunological/clinical results (Codreanu, 2011).
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OBJECTIVES:Wound complications following surgical procedures are a significant
cost burden to the health care system and have been identified as one of the
hospital-acquired infections not reimbursed by payers. Surgical site infections
have been associated with both an increased hospital stay of 9.58 extra days and
$38,656 in additional medical charges, and postoperative dehiscence can add as
much as 9.42 extra days, resulting in $40,323 in additional charges. A health eco-
nomicmodel was developed to demonstrate potential cost savings associatedwith
using closed incision management (CIM*) to apply negative pressure wound ther-
apy (NPWT) over clean closed surgical incisions in patients treated for an open
fracture of the tibia and fibula. METHODS: The hypothetical economic model ap-
plied national cost dollars to clinical outcomes of the Stannard et al randomized
controlled trial (RCT) usingNPWT†over closed incisions. National cost data (Thom-
son Reuters custom report) were selected using the diagnosis codes related to the
population of patients within the Stannard et al RCT, which were open fracture of
the tibia and fibula with complications such as infection and dehiscence (ICD9
79.36). The infection rates (10%, 14/141 patients NPWT and 19%, 23/122 patients
Control [standard of care], p0.049) and dehiscence rates (8.6%, 12/141 NPWT and
16.5%, 20/122 Control, p0.044) were calculated from the Stannard et al RCT and
were applied to a hypothetical 100 patient population (50 CIM and 50 Control).
RESULTS: Reduced infection and dehiscence rates in this patient population re-
sulted in potential per patient cost savings of $5338 for infection and $1586 for
dehiscence with CIM. CONCLUSIONS: These findings illustrate the potential cost
effectiveness of CIM over closed incisions of high-risk fractures. *Prevena™ Inci-
sion Management System and †V.A.C. Therapy; KCI USA, Inc., San Antonio, TX,
USA
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Current available methods in Mexico for blood group typing are made through a
tube serological antigen/antibody reaction (TST) but has limitations due to the lack
of blood weak antigens detection that generate incomplete information on blood
group phenotype and potential recipient alloimmunization that can cause life
threatening transfusion-related reactions as acute lung injury and hemolytic
reactions. OBJECTIVES: To develop an economic model based in Mexican Institute
of Social Security (IMSS) resource payments to evaluate the cost-effectiveness of
ANDCK versus TST for the determination of blood erythrocyte variants in Mexico.
METHODS: A two branch decision tree model was developed to evaluate and com-
pare the cost-effectiveness in Mexican pesos (MxP) of ANDCK and TST for the
determination of blood erythrocyte variants. The effectivenessmeasure was blood
group typing errors rate obtained from published clinical trials. Resource use and
cost were obtained from expert interviews and IMSS published data respectively.
The model estimated cost per patient and incremental cost-effectiveness ratios
(ICER). Costs and effectiveness do not were discounted. A deterministic sensitivity
analysis was also performed. RESULTS: The rate of blood group typing errors was
0.07% for ANDCK group and 0.17% for TST group. Cost per patientwas always lower
with ANDCK ($2,340.00 MxP) than TST ($3,921.21 MxP) showing that ANDCK was
the dominant alternative. Sensitivity analysis shows model robustness and con-
firms ANDCK as dominant alternative. CONCLUSIONS: Our results show that
ANDCK is cost-effective for the determination of blood erythrocyte variants in
Mexico and should be considered by clinicians and decision makers as a favorable
option for the determination of blood group typing in order to avoid life threatening
transfusion-related reactions.
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TO PREVENT CENTRAL-LINE ASSOCIATED BLOODSTREAM INFECTIONS AND
LOCAL SITE INFECTIONS IN CANADIAN HOSPITALS: AN ECONOMIC ANALYSIS
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OBJECTIVES: The objective of the study was to evaluate the economic impact of
adding the use of chlorhexidine gluconate (CHG) impregnated sponge dressings to
Canadianhospitals’ standard infection prevention routine. The current standard of
care for catheter insertion in Canada involves hand hygiene, skin preparation and
transparent film dressings. The aim of this study was to determine whether the
addition of CHG impregnated sponge dressings to catheter insertion procedurewas
cost-effective. METHODS: The economic model was populated with clinical and
economic data obtained from peer-reviewed literature along with case-costing
data froma large Canadian hospital network. One and twoway sensitivity analyses
were conducted on economic and clinical parameters to ensure robustness.
RESULTS: Based on model calculations using a hypothetical hospital with 400 in-
patient beds and 20 intensive care unit beds, the use of CHG dressings would
reduce the number of CLABSIs from 107 to 43 annually, and would reduce the
number of local site infections from 430 to 258 annually. The model demonstrates
cost savings through the reduction of CLABSI and local site infections as well as
through decreased nursing costs. Themodel establishes that the use of CHG dress-
ings has the potential to provide $869, 867.49 of net cost savings in one hospital per
year. CONCLUSIONS: The use of chlorhexidine gluconate impregnated sponge
dressings for central venous and arterial catheter insertion sites proves to be a
cost-effective intervention in Canadian hospitals.
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OBJECTIVES: The aim of this study is to evaluate the cost-effectiveness of CT cor-
onary angiography (CTCA) and myocardial SPECT for ischemic heart disease in
patients with chest pain.METHODS:We assessed cost-effective of CTCA andmyo-
cardial SPECT for patients with intermediate risk with pre-test likelihood of 10-90.
The model was analyzed by using diagnosis accuracy and QALY. The model using
diagnosis accuracy used the number of patients accurately diagnosed among 1000
persons as the effect, and reflecting only themedical expenses for tests as the cost.
In the model using QALY, a decision tree was developed and the time horizon was
1 year. Utility weights were calculated using questionnaires for each case from
general population. Costs were calculated through analysis of Health Insurance
Review & Assessment Service claim data and transition probabilities were esti-
mated from retrospective cohort data. Analyses were conducted from the Health-
care system perspectives. RESULTS: In the model using diagnosis accuracy, CTCA
appeared to be more effective (224.41 correct diagnosis) and even less expensive
(US$58,819 per 1,000 persons) thanmyocardial SPECT proposed to be the dominate
alternative. In themodel using QALY, CTCA showedmore effective (0.00040QALYs)
and less cost (US$465) than myocardial SPECT. Sensitivity analysis was performed
for transition probabilities, utilityweights and costs. The results of sensitivity anal-
ysis were robust. In subgroup analysis, myocardial SPECT showed cost-effective in
patients with pre-test likelihood of 30-60. CONCLUSIONS: In conclusion, cost-ef-
fective analysis between CTCA andmyocardial SPECT indicated that CTCAwas the
cost-effective test for both models using diagnosis accuracy and the one using
QALY in patients with intermediate risk with pre-test likelihood of 10-90.
PMD38
COST MINIMIZATION ANALYSIS OF A MULTI-SITE RANDOMIZED CLINICAL
TRIAL OF HOME-BASED VERSUS LABORATORY-BASED TESTING FOR THE
DIAGNOSIS AND TREATMENT OF OBSTRUCTIVE SLEEP APNEA (HOMEPAP
STUDY)
Kim RD1, Kapur VK2, Redline bruch J3, Rueschman M4, Rosen CL5, Redline S6, Ramsey S7
1Pharmaceutical Outcomes Research and Policy Program, Univerisity of Washington, Seattle,
WA, USA, 2University of Washington, Seattle, WA, USA, 3Mathematica Policy Research,
Cambridge, MA, USA, 4Brigham and Women’s Hospital, Boston, MA, USA, 5University Hospitals,
Case Western Reserve University, Cleveland, OH, USA, 6Brigham and Women’s Hospital and
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA, 7Fred
Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA
OBJECTIVES: The cost implications of adopting portablemonitoring devices for the
diagnosis of obstructive sleep apnea (OSA) are largely unknown.We conducted an
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economic analysis of the HomePAP study, a multi-center randomized clinical trial
that compared home-based versus lab-based testing for themanagement of OSA in
accredited sleep centers. METHODS: A total of 373 subjects with a high risk for
moderate to severe OSA were randomized to either unattended, home-based lim-
ited channel portable monitoring for diagnosis of OSA followed by unattended
auto-titration with continuous positive airway pressure (CPAP), versus a tra-
ditional pathway of in-laboratory sleep study and CPAP titration. Given that 3
month outcomes were not inferior for the home arm in acceptance, adherence,
and functional improvements, we pursued a cost minimization analysis from
the payer perspective. 2011 Medicare price weights were used. Interpretation of
home-based CPAP titration is currently not reimbursed by Medicare, so we es-
timated it as one-third the Medicare reimbursement for interpreting a lab-based
sleep study. RESULTS: Per subject costs, as randomized, were $1265 for the lab-
based pathway and $927 for the home-based pathway (base case). In the per pro-
tocol analysis (patients adherent to CPAP for 3months), per subject costswere even
higher for the lab-based pathway ($1,863 vs. $866). In a sensitivity analysis, even
after increasing the Medicare reimbursement for home-based titration studies to
100% that of lab-based studies, per subject costs per protocol were still higher for
the lab-based pathway ($1,863 vs. $953). CONCLUSIONS: From the payer perspec-
tive, there are higher costs incurred within a lab-based versus a home-based diag-
nostic pathwaywithout superiority in outcomes. The results suggest that the care-
ful use of home-based sleep studies administered by trained personnel at board-
certified sleep centers could save money without compromising short term
outcomes.
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OBJECTIVES: Improvement in glycaemic control associated with Continuous Glu-
cose Monitoring (CGM) use leads to a reduction of costly diabetes-related compli-
cations. Our aim was to estimate the health economics benefits of CGM compared
to Self-Monitoring of Blood Glucose (SMBG) in type 1 diabetes (T1DM) in the Swed-
ish setting.METHODS: The Core DiabetesModel (CDM) is an internet-based, highly
validated, computer-simulation model to determine the long-term health out-
comes and economic consequences of diabetes interventions. This model was
used to evaluate the cost-effectiveness of CGM versus SMBG in T1DM over a life-
time horizon. Results from a recently published meta-analysis comparing CGM
versus SMBG and a real life observational Swedish study were used. The meta-
analysis showed that for a cohort of T1DM with average baseline HbA1c of 8.1%,
mean baseline age of 27 years and diabetes duration of 13 years, everyday use of
CGM led to HbA1c reduction of -0.76% versus -0.13%, for CGM and SMBG respec-
tively. The observational study demonstrated a reduction from 7.11 to 4.35 daily
blood glucose tests when using CGM compared to SMBG only. RESULTS: The Incre-
mental-Cost-Effectiveness-Ratio (ICER) for CGM vs. SMBG only was 369,253SEK
(41,940€) per Quality-Adjusted-Life-Year gained (QALYg), based on combined direct
and indirect costs. Undiscounted life expectancy was improved by 1.5 years. The
improvement in discounted QALY was 0.62 in favour of CGM. CGM related costs
were partially offset by the savings due to the reduction in long-term complica-
tions. CGM usage compared to SMBG increased the mean time alive free from
complications. Sensitivity analysis has been conducted. CONCLUSIONS: Our anal-
ysis showed that CGM is very cost-effective compared to SMBG over a lifetime
horizon in T1DM patients in the Swedish setting and can lead to an increase in life
expectancy.
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OBJECTIVES: To estimate the cost-effectiveness of delayed troponin testing for
myocardial infarction (MI), as recommended in current guidelines, compared to
troponin testing at presentation. METHODS: We developed a decision analytic
model to estimate the cost-effectiveness of diagnostic strategies for MI, measured
as the incremental cost per quality-adjusted life year (QALY) gained by each strat-
egy compared to the next most effective alternative. The model was applied to a
hypothetical population of 1000 patients attending hospital with symptoms sug-
gesting MI but a normal or non-diagnostic electrocardiogram (ECG) and no major
co-morbidities requiring hospital treatment. Delayed troponin testing (10-12 hours
after symptom onset) was compared to standard and high sensitivity troponin
testing at presentation and no testing. We tested three different scenarios regard-
ing delayed testing, in relation to the delay between results being available and a
decision beingmade, the “doctor on demand” scenario, inwhichmedical staffwere
available 24 hours a day to make a disposition decision within one hour of the
results being available, twice daily ward round and once daily ward round scenar-
ios where medical staff were only available at twice daily ward rounds and once
dailyward rounds, respectively. RESULTS: In all scenarios tested presentation high
sensitivity troponin testing was the most effective strategy with an incremental
cost-effectiveness ratio (ICER) below the £20,000/QALY threshold. Delayed tro-
ponin testing was only likely to be cost-effective if a discharge decision could be
made as soon as a negative result was available and the £30,000/QALY threshold
was used. CONCLUSIONS: Delayed troponin testing is unlikely to be cost-effective
compared to high sensitivity troponin testing at presentation in most scenarios.
The current guidelines recommending 10-12 hour troponin testing does not appear
to promote cost-effective use of hospital resources, unless services are in place to
allow rapid decision making once delayed test results are available.
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OBJECTIVES: To estimate the clinical and economic consequences of Continuous
Subcutaneous Insulin Infusion (CSII) versus Multiple Daily Injection (MDI) for type
1 diabetes (DM1) through cost-utility analysis, from the perspective of the Mexican
Social Security Institute (IMSS).METHODS:We used a validated simulation model
(CORE Model), together with published literature for clinical, quality of life and
therapy effectiveness. Demographic information and incident complications for
131 patients with DM1 from the 21st Century Hospital (IMSS) were incorporated
into the simulation. Direct and indirect cost data were obtained from the IMSS and
Secretary of Health (SSA) National Economic Information. A simulation of the clin-
ical and economic consequences in a lifetime follow-up of therapy was performed.
Direct and indirect costs with a discount rate of 3% were input to the model.
RESULTS: Lifetime, treatmentwithCSII gained 8.5 quality-adjusted life years vs. 7.6
quality-adjusted life years for MDI therapy. Over 50 years of treatment, CSII versus
MDI, had an incremental direct cost of 422,187 Mexican Pesos (MXP) per quality
adjusted life year (QALY). For indirect costs, CSII is cost saving relative to MDI
(saving 158,831 MXP/QALY). For combined direct and indirect costs, the incremen-
tal cost-effectiveness ratio for CSII vs. MDIwas 283,356MXP/QALY.CONCLUSIONS:
Better glycemic control, and increased quality of life for DM1 patients treated with
CSII demonstrated incremental cost effectiveness below the willingness to pay
threshold set by the World Health Organization (510,300 MXP). This makes CSII a
cost effective treatment alternative to MDI in Mexico. The higher incremental di-
rect cost of CSII relative to MDI is compensated by the savings in indirect costs.
MEDICAL DEVICE/DIAGNOSTICS – Patient-Reported Outcomes & Patient
Preference Studies
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OBJECTIVES: Back and leg pain arising from spinal stenosis with degenerative
spondylolisthesis have a substantial impact on the quality of life of patients. Using
data on collected costs, resource utilization, and patient-reported outcomes from
an ongoing randomized clinical trial comparing a novel, motion-preserving inter-
laminar stabilization device (coflex®) to control (instrumented posterolateral spi-
nal fusion) among patients with spinal stenosis and spondylolisthesis, we report
and compare the relative cost-effectiveness of these two treatments.METHODS: A
model was developed to compare interventions. The primary source for the mod-
el’s clinical input parameterswas the recent investigational clinical trial of coflex®,
supporting premarket approval application to FDA. Treatment patterns over five
years were estimated based on claims data analyses and expert opinion. Oswestry
Disability Index scores collected during the trial were converted to utilities. A third-
party payer perspective was used, and costs (US 2011$) and outcomes were dis-
counted at 3% annually. Both Medicare and private-payer costs were modeled.
Sensitivity analyses examined the influence of costs, utilities, and discount rates.
RESULTS: Patients receiving coflexhadhigher success rates and lower costs in both
theMedicare and private payermodels. Payments over five yearswere estimated at
$14,534 for coflex® implant patients compared to $25,620 for controls (Medicare
costs; $17,714 vs. $31,747 for private coverage). Utilities were higher for coflex®-
treated patients at all assessments, and totaled 3.03 quality-adjusted life years
(QALY) compared to 2.98 for controls. Incremental cost-effectiveness could not be
calculated, as the novel implant dominated, demonstrating both lower costs and
better outcomes. Sensitivity analyses identified no scenario in which fusion was
preferred over the coflex®. CONCLUSIONS: The use of coflex® to treat stenosis and
spondylolisthesis is cost saving, and associated with improved patient outcomes.
Subgroup analyses comparing indications and patient characteristics should be
conducted to confirm robustness of findings.
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OBJECTIVES: Current multiple sclerosis (MS) disease modifying medications fre-
quently require the use of self-injection devices. These can present varied burdens
for patients in terms of their portability, complexity in preparation and potential
for causing discomfort. Furthermore, the necessity to self-inject is closely associ-
atedwith levels of adherence to treatment and optimising the acceptability of such
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